Resverlogix Corp. (RVX.TO)
CAD 0.05
(12.5%)
CAD 0.05
(12.5%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2022 | 67.39 Million USD | -3.52% |
| 2021 | 69.85 Million USD | 137944.7% |
| 2020 | 50.6 Thousand USD | -99.93% |
| 2019 | 75.49 Million USD | -66.3% |
| 2018 | 224 Million USD | 143.61% |
| 2017 | 91.95 Million USD | -18.22% |
| 2016 | 112.43 Million USD | 16.48% |
| 2015 | 96.52 Million USD | 1.73% |
| 2014 | 94.88 Million USD | 43.24% |
| 2013 | 66.24 Million USD | 32.48% |
| 2012 | 50 Million USD | 419.21% |
| 2011 | 9.63 Million USD | 133.34% |
| 2010 | 4.12 Million USD | 3.96% |
| 2009 | 3.96 Million USD | -45.6% |
| 2008 | 7.29 Million USD | -52.21% |
| 2007 | 15.26 Million USD | -4.68% |
| 2006 | 16.01 Million USD | 2664.7% |
| 2005 | 579.35 Thousand USD | 63.95% |
| 2004 | 353.36 Thousand USD | 262.06% |
| 2003 | 97.59 Thousand USD | -30.21% |
| 2002 | 139.85 Thousand USD | 292.32% |
| 2001 | 35.64 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q1 | 71.86 Thousand USD | -99.89% |
| 2023 Q2 | 75.11 Million USD | 104435.21% |
| 2023 Q3 | 79.35 Million USD | 5.64% |
| 2022 FY | 67.39 Million USD | -3.52% |
| 2022 Q4 | 67.39 Million USD | -4.4% |
| 2022 Q1 | 70.92 Million USD | 1.53% |
| 2022 Q2 | 70.04 Million USD | -1.23% |
| 2022 Q3 | 70.49 Million USD | 0.64% |
| 2021 FY | 69.85 Million USD | 137944.7% |
| 2021 Q4 | 69.85 Million USD | 27.44% |
| 2021 Q1 | 49.82 Million USD | 0.0% |
| 2021 Q2 | 52.75 Million USD | 5.88% |
| 2021 Q3 | 54.81 Million USD | 3.9% |
| 2020 Q1 | 75.49 Million USD | -13.19% |
| 2020 FY | 50.6 Thousand USD | -99.93% |
| 2020 Q2 | 76.58 Million USD | 1.45% |
| 2020 Q3 | 63.31 Million USD | -17.33% |
| 2019 Q4 | 86.95 Million USD | -8.91% |
| 2019 Q3 | 95.46 Million USD | -55.43% |
| 2019 Q2 | 214.17 Million USD | -4.39% |
| 2019 FY | 75.49 Million USD | -66.3% |
| 2019 Q1 | 224 Million USD | 31.11% |
| 2018 Q4 | 170.86 Million USD | 1.45% |
| 2018 FY | 224 Million USD | 143.61% |
| 2018 Q3 | 168.41 Million USD | 14.38% |
| 2018 Q2 | 147.23 Million USD | 60.12% |
| 2018 Q1 | 91.95 Million USD | 5.65% |
| 2017 Q3 | 128.61 Million USD | 6.47% |
| 2017 Q2 | 120.79 Million USD | 7.44% |
| 2017 Q1 | 112.43 Million USD | 8.12% |
| 2017 FY | 91.95 Million USD | -18.22% |
| 2017 Q4 | 87.03 Million USD | -32.32% |
| 2016 Q2 | 94.65 Million USD | -1.93% |
| 2016 FY | 112.43 Million USD | 16.48% |
| 2016 Q4 | 103.99 Million USD | 5.06% |
| 2016 Q1 | 96.52 Million USD | 8.98% |
| 2016 Q3 | 98.97 Million USD | 4.56% |
| 2015 Q1 | 94.88 Million USD | 24.36% |
| 2015 Q4 | 88.57 Million USD | 0.21% |
| 2015 FY | 96.52 Million USD | 1.73% |
| 2015 Q3 | 88.38 Million USD | -1.66% |
| 2015 Q2 | 89.87 Million USD | -5.28% |
| 2014 Q4 | 76.29 Million USD | -4.7% |
| 2014 Q3 | 80.05 Million USD | 38.82% |
| 2014 Q2 | 57.67 Million USD | -12.94% |
| 2014 Q1 | 66.24 Million USD | -1.95% |
| 2014 FY | 94.88 Million USD | 43.24% |
| 2013 Q2 | 89.11 Million USD | 78.23% |
| 2013 FY | 66.24 Million USD | 32.48% |
| 2013 Q4 | 67.55 Million USD | -19.91% |
| 2013 Q3 | 84.35 Million USD | -5.34% |
| 2013 Q1 | 50 Million USD | 46.07% |
| 2012 Q3 | 28.56 Million USD | 169.07% |
| 2012 Q1 | 9.63 Million USD | 7.54% |
| 2012 Q2 | 10.61 Million USD | 10.25% |
| 2012 FY | 50 Million USD | 419.21% |
| 2012 Q4 | 34.22 Million USD | 19.82% |
| 2011 FY | 9.63 Million USD | 133.34% |
| 2011 Q4 | 8.95 Million USD | -2.66% |
| 2011 Q1 | 4.12 Million USD | 102.66% |
| 2011 Q2 | 10.41 Million USD | 152.41% |
| 2011 Q3 | 9.2 Million USD | -11.68% |
| 2010 Q3 | 2.26 Million USD | 10.13% |
| 2010 FY | 4.12 Million USD | 3.96% |
| 2010 Q1 | 3.96 Million USD | 88.77% |
| 2010 Q4 | 2.03 Million USD | -9.96% |
| 2010 Q2 | 2.05 Million USD | -48.27% |
| 2009 Q4 | 2.1 Million USD | -68.39% |
| 2009 Q2 | 6.7 Million USD | -8.15% |
| 2009 FY | 3.96 Million USD | -45.6% |
| 2009 Q1 | 7.29 Million USD | -16.1% |
| 2009 Q3 | 6.65 Million USD | -0.74% |
| 2008 FY | 7.29 Million USD | -52.21% |
| 2008 Q1 | 15.26 Million USD | -2.02% |
| 2008 Q2 | 13.74 Million USD | -9.95% |
| 2008 Q3 | 7.65 Million USD | -44.33% |
| 2008 Q4 | 8.69 Million USD | 13.63% |
| 2007 Q3 | 18.18 Million USD | -30.46% |
| 2007 Q4 | 15.58 Million USD | -14.33% |
| 2007 Q2 | 26.15 Million USD | 63.29% |
| 2007 Q1 | 16.01 Million USD | -6.5% |
| 2007 FY | 15.26 Million USD | -4.68% |
| 2006 Q1 | 579.35 Thousand USD | 158.33% |
| 2006 FY | 16.01 Million USD | 2664.7% |
| 2006 Q4 | 17.13 Million USD | 1518.97% |
| 2006 Q2 | 564.13 Thousand USD | -2.63% |
| 2006 Q3 | 1.05 Million USD | 87.57% |
| 2005 Q4 | 224.27 Thousand USD | -42.69% |
| 2005 FY | 579.35 Thousand USD | 63.95% |
| 2005 Q1 | 353.36 Thousand USD | 87.74% |
| 2005 Q2 | 378.65 Thousand USD | 7.16% |
| 2005 Q3 | 391.31 Thousand USD | 3.34% |
| 2004 Q3 | 160.66 Thousand USD | -0.64% |
| 2004 Q4 | 188.22 Thousand USD | 17.15% |
| 2004 Q2 | 161.7 Thousand USD | 65.68% |
| 2004 Q1 | 97.59 Thousand USD | -4.21% |
| 2004 FY | 353.36 Thousand USD | 262.06% |
| 2003 Q2 | 129.2 Thousand USD | -7.61% |
| 2003 Q1 | 139.85 Thousand USD | 89.87% |
| 2003 Q3 | 100.92 Thousand USD | -21.89% |
| 2003 Q4 | 101.88 Thousand USD | 0.96% |
| 2003 FY | 97.59 Thousand USD | -30.21% |
| 2002 Q2 | 10.37 Thousand USD | -33.89% |
| 2002 Q3 | 4805.84 USD | -53.67% |
| 2002 FY | 139.85 Thousand USD | 292.32% |
| 2002 Q4 | 73.65 Thousand USD | 1432.6% |
| 2002 Q1 | 15.69 Thousand USD | 0.0% |
| 2001 FY | 35.64 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Appili Therapeutics Inc. | 12.41 Million CAD | -442.851% |
| Eupraxia Pharmaceuticals Inc. | 25.54 Million CAD | -163.818% |
| Helix BioPharma Corp. | 1.57 Million CAD | -4168.271% |
| Microbix Biosystems Inc. | 11.02 Million CAD | -511.106% |
| Medicenna Therapeutics Corp. | 13.94 Million CAD | -383.368% |
| Satellos Bioscience Inc. | 3.62 Million CAD | -1759.713% |
| Oncolytics Biotech Inc. | 11.25 Million CAD | -498.703% |
| Sernova Corp. | 9.59 Million CAD | -602.607% |